a developer of drugs to improve the treatment of cancer
Industry Biotechnology
A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with INZY. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then INZY could also see price increases.
Ticker / NAME | Correlation To ABUS | 1D Price Change % | ||
---|---|---|---|---|
ABUS | 100% | +3.10% | ||
INZY - ABUS | 41% Loosely correlated | -5.60% | ||
VIR - ABUS | 39% Loosely correlated | -5.81% | ||
ABCL - ABUS | 39% Loosely correlated | -2.34% | ||
ERAS - ABUS | 38% Loosely correlated | -5.19% | ||
SCPH - ABUS | 38% Loosely correlated | -2.75% | ||
More |
Ticker / NAME | Correlation To ABUS | 1D Price Change % |
---|---|---|
ABUS | 100% | +3.10% |
drugs theme (265 stocks) | 46% Loosely correlated | +5.37% |
biotechnology theme (248 stocks) | 45% Loosely correlated | +5.56% |
cancer theme (87 stocks) | 41% Loosely correlated | +0.89% |
stem cells theme (21 stocks) | 40% Loosely correlated | +0.41% |
north america theme (189 stocks) | 32% Poorly correlated | -0.16% |